Futura provides US regulatory and commercial update

 Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to provide an update on regulatory processes and commercial activities for MED3000. MED3000 is the Company’s breakthrough, topical gel formulation for treatment of erectile dysfunction (ED).  Futura is seeking marketing approval for the product in Europe and the USA for use as an over-the-counter (OTC) clinical treatment of ED thereby removing the need for a doctor’s prescription, with plans to file in other regions in due course.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...